Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
life sciences & biomedicine (9) 9
science & technology (9) 9
female (8) 8
middle aged (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
male (7) 7
oncology (7) 7
adult (6) 6
aged (6) 6
biological and medical sciences (5) 5
chemotherapy (5) 5
medical sciences (5) 5
cancer therapies (4) 4
disease-free survival (4) 4
solid tumors (4) 4
tumors (4) 4
antineoplastic agents (3) 3
metastasis (3) 3
neoplasm metastasis (3) 3
patients (3) 3
treatment outcome (3) 3
advanced colorectal cancer (2) 2
aged, 80 and over (2) 2
alanine (2) 2
alanine transaminase (2) 2
alanine transaminase - blood (2) 2
aminopyridines - administration & dosage (2) 2
aminopyridines - adverse effects (2) 2
analysis (2) 2
antimitotic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
aspartate aminotransferase (2) 2
aspartate aminotransferases - blood (2) 2
breast cancer (2) 2
breast neoplasms - drug therapy (2) 2
cancer (2) 2
carboplatin - administration & dosage (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
class i phosphatidylinositol 3-kinases (2) 2
clinical study (2) 2
colorectal neoplasms - drug therapy (2) 2
colorectal neoplasms - mortality (2) 2
colorectal neoplasms - pathology (2) 2
endocrine therapy (2) 2
general & internal medicine (2) 2
hematology, oncology and palliative medicine (2) 2
lung cancer (2) 2
lung cancer, non-small cell (2) 2
lung neoplasms - drug therapy (2) 2
lymphoma (2) 2
lymphomas (2) 2
medicine, general & internal (2) 2
metastases (2) 2
morpholines - administration & dosage (2) 2
morpholines - adverse effects (2) 2
motivation (2) 2
mutation (2) 2
pharmacology. drug treatments (2) 2
prognosis (2) 2
pyrimidines - adverse effects (2) 2
response evaluation criteria in solid tumors (2) 2
retreatment (2) 2
sulfones - adverse effects (2) 2
survival (2) 2
survival analysis (2) 2
survival rate (2) 2
taxoids - therapeutic use (2) 2
toxicity (2) 2
1-phosphatidylinositol 3-kinase (1) 1
5-fu-based chemotherapy (1) 1
abdomen (1) 1
abdominal neoplasms - drug therapy (1) 1
abdominal neoplasms - pathology (1) 1
abdominal neoplasms - surgery (1) 1
abridged index medicus (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - pathology (1) 1
administration, oral (1) 1
advanced breast cancer (1) 1
alternatives (1) 1
anaplastic lymphoma kinase (1) 1
anesthesia. intensive care medicine. transfusions. cell therapy and gene therapy (1) 1
anthracycline pretreatment (1) 1
anthracyclines - therapeutic use (1) 1
anti-inflammatory agents, non-steroidal - administration & dosage (1) 1
anticoagulants (1) 1
antimetabolites, antineoplastic - adverse effects (1) 1
antimetabolites, antineoplastic - therapeutic use (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
aromatase (1) 1
biomarkers, tumor - genetics (1) 1
biomarkers, tumor - metabolism (1) 1
bkm120 (1) 1
blood (1) 1
bowel occlusion (1) 1
breast neoplasms - chemistry (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
by Shaw, Alice T, Dr and Kim, Tae Min, MD and Crinò, Lucio, Prof and Gridelli, Cesare, MD and Kiura, Katsuyuki, MD and Liu, Geoffrey, MD and Novello, Silvia, Prof and Bearz, Alessandra, MD and Gautschi, Oliver, MD and Mok, Tony, Prof and Nishio, Makoto, MD and Scagliotti, Giorgio, Prof and Spigel, David R, MD and Deudon, Stéphanie, PharmD and Zheng, Cheng, PhD and Pantano, Serafino, PhD and Urban, Patrick, MD and Massacesi, Cristian, MD and Viraswami-Appanna, Kalyanee, PhD and Felip, Enriqueta, MD
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 874 - 886
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Sulfones - therapeutic use | Pyrazoles - therapeutic use | gamma-Glutamyltransferase - blood | Humans | Middle Aged | Sulfones - adverse effects | Lung Neoplasms - pathology | Male | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Adult | Female | Pyridines - therapeutic use | Crizotinib | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Docetaxel | Disease Progression | Disease-Free Survival | Retreatment | Aspartate Aminotransferases - blood | Receptor Protein-Tyrosine Kinases - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - therapeutic use | Pyrimidines - therapeutic use | Gene Rearrangement | Pyrimidines - adverse effects | Carcinoma, Non-Small-Cell Lung - drug therapy | Platinum Compounds - administration & dosage | Neoplasm Staging | Care and treatment | Chemotherapy | Lymphomas | Research institutes | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
by Soria, Jean-Charles, Prof and Tan, Daniel S W, MD and Chiari, Rita, MD and Wu, Yi-Long, Prof and Paz-Ares, Luis, Prof and Wolf, Juergen, Prof and Geater, Sarayut L, MD and Orlov, Sergey, Prof and Cortinovis, Diego, MD and Yu, Chong-Jen, Prof and Hochmair, Maximillian, MD and Cortot, Alexis B, Prof and Tsai, Chun-Ming, Prof and Moro-Sibilot, Denis, MD and Campelo, Rosario G, MD and McCulloch, Tracey, MSc and Sen, Paramita, PhD and Dugan, Margaret, MD and Pantano, Serafino, PhD and Branle, Fabrice, MD and Massacesi, Cristian, MD and de Castro, Gilberto, MD
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10072, pp. 917 - 929
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Antineoplastic Agents - administration & dosage | Cisplatin - administration & dosage | Carboplatin - adverse effects | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Pemetrexed - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Cisplatin - adverse effects | Pemetrexed - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Legislators | Chemotherapy | Lymphomas | Lung cancer, Non-small cell | Genomics | Cancer | Analysis | Pain | Lung cancer | Radiation therapy | Metastasis | Cancer therapies | Patients | Lymphoma | Blood | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
by Baselga, José, Prof and Im, Seock-Ah, Prof and Iwata, Hiroji, MD and Cortés, Javier, MD and De Laurentiis, Michele, MD and Jiang, Zefei, Prof and Arteaga, Carlos L, Prof and Jonat, Walter, Prof and Clemons, Mark, Prof and Ito, Yoshinori, MD and Awada, Ahmad, Prof and Chia, Stephen, MD and Jagiełło-Gruszfeld, Agnieszka, MD and Pistilli, Barbara, MD and Tseng, Ling-Ming, MD and Hurvitz, Sara, MD and Masuda, Norikazu, MD and Takahashi, Masato, MD and Vuylsteke, Peter, MD and Hachemi, Soulef, PhD and Dharan, Bharani, MS and Di Tomaso, Emmanuelle, PhD and Urban, Patrick, MD and Massacesi, Cristian, MD and Campone, Mario, Prof
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 904 - 916
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Estradiol - analogs & derivatives | Humans | Middle Aged | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Receptors, Estrogen - analysis | Fulvestrant | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Neoplasm Metastasis | Hyperglycemia - chemically induced | DNA, Neoplasm - blood | DNA Mutational Analysis | Exanthema - chemically induced | Postmenopause | Female | Morpholines - adverse effects | Aminopyridines - administration & dosage | Drug Eruptions - etiology | Double-Blind Method | Morpholines - administration & dosage | Estradiol - administration & dosage | Survival Rate | Signal Transduction - genetics | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Retreatment | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Aspartate Aminotransferases - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Clinical trials | Product development | Breast cancer | Postmenopausal women | Hormones | Antineoplastic agents | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
by Rodon, Jordi and Braña, Irene and Siu, Lillian L and De Jonge, Maja J and Homji, Natasha and Mills, David and Di Tomaso, Emmanuelle and Sarr, Celine and Trandafir, Lucia and Massacesi, Cristian and Eskens, Ferry and Bendell, Johanna C
Investigational new drugs, ISSN 0167-6997, 8/2014, Volume 32, Issue 4, pp. 670 - 681
Buparlisib | Medicine & Public Health | Targeted therapy | PI3K inhibitor | Oncology | Solid tumors | Pharmacology/Toxicology | BKM120 | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Tumors | Neoplasms - metabolism | Aminopyridines - administration & dosage | Administration, Oral | Humans | Middle Aged | Morpholines - administration & dosage | Aminopyridines - adverse effects | PTEN Phosphohydrolase - metabolism | Male | Phosphatidylinositol 3-Kinases - metabolism | Protein Kinase Inhibitors - adverse effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Class I Phosphatidylinositol 3-Kinases | Biomarkers, Tumor - metabolism | Adult | Female | Aged | Morpholines - adverse effects | Antimitotic agents | Complications and side effects | Dosage and administration | Research | Drug therapy | Inhibitor drugs | Statistical analysis | Patients | Cancer therapies | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Sustained release octreotide may have a role in the treatment of malignant bowel obstruction
by Massacesi, Cristian and Galeazzi, Giordano
Palliative medicine, ISSN 0269-2163, 10/2006, Volume 20, Issue 7, pp. 715 - 716
Bowel occlusion | Octreotide | Solid tumors | Vomiting | Nasogastric tube | Health Care Sciences & Services | Medicine, General & Internal | Public, Environmental & Occupational Health | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Public health. Hygiene-occupational medicine | Public health. Hygiene | Ethics | Miscellaneous | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy | Biological and medical sciences | Clinical death. Palliative care. Organ gift and preservation | Medical sciences | Humans | Middle Aged | Gastrointestinal Agents - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Delayed-Action Preparations - administration & dosage | Nausea - prevention & control | Intestinal Obstruction - drug therapy | Pain - drug therapy | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Female | Aged | Octreotide - administration & dosage | Rectal Neoplasms - drug therapy | Vomiting - prevention & control | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Capecitabine and Mitomycin C Is an Effective Combination for Anthracycline- and Taxane-Resistant Metastatic Breast Cancer
by Massacesi, Cristian and La Cesa, Annalisa and Marcucci, Fabiana and Pilone, Alberta and Rocchi, Marco B.L and Zepponi, Laura and Santini, Daniele and Tonini, Giuseppe and Burattini, Luciano
Oncology, ISSN 0030-2414, 10/2006, Volume 70, Issue 4, pp. 294 - 300
Clinical Study | Advanced breast cancer | Capecitabine | Taxane pretreatment | Endocrine therapy | Visceral metastases | Anthracycline pretreatment | Mitomycin C | Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | Medical sciences | Tumors | Mitomycin - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Humans | Middle Aged | Drug Resistance, Neoplasm | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Taxoids - therapeutic use | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Breast Neoplasms - mortality | Deoxycytidine - adverse effects | Female | Anthracyclines - therapeutic use | Mitomycin - administration & dosage | Deoxycytidine - analogs & derivatives | Survival analysis | Chemotherapy | Side effects | Toxicity | Breast cancer | Alternatives | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens
by Massacesi, Cristian and Pistilli, Barbara and Valeri, Michele and Lippe, Paolo and Rocchi, Marco B. L and Cellerino, Riccardo and Piga, Andrea
American journal of clinical oncology, ISSN 0277-3732, 2002, Volume 25, Issue 2, pp. 140 - 148
Short-term survivors | Advanced colorectal cancer | Progression predictor factors | 5-FU-based chemotherapy | Metastatic colorectal cancer | Clinical prognostic factors | Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Chemotherapy | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Colorectal Neoplasms - mortality | Multivariate Analysis | Adenocarcinoma - pathology | Prognosis | Humans | Middle Aged | Logistic Models | Male | Adenocarcinoma - drug therapy | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - drug therapy | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Colorectal Neoplasms - pathology | Adenocarcinoma - mortality | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Desmoplastic Small Round Cell Tumour: A Description of Two Cases and Review of the Literature
by Lippe, Paolo and Berardi, Rossana and Cappelletti, Claudia and Massacesi, Cristian and Mattioli, Rodolfo and Latini, Luciano and Cellerino, Riccardo
Oncology, ISSN 0030-2414, 12/2002, Volume 64, Issue 1, pp. 14 - 17
Clinical Study | Desmoplastic tumours | Polychemotherapy | Carboplatin doxorubicin and etoposide regimen | Objective response | Small round cell tumour | Life Sciences & Biomedicine | Oncology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Biological and medical sciences | Medical sciences | Abdomen | Tumors | Carcinoma, Small Cell - secondary | Carcinoma, Small Cell - surgery | Cyclophosphamide - administration & dosage | Prognosis | Abdominal Neoplasms - drug therapy | Carcinoma, Small Cell - drug therapy | Humans | Liver Neoplasms - drug therapy | Salvage Therapy | Carboplatin - administration & dosage | Etoposide - administration & dosage | Liver Neoplasms - surgery | Male | Combined Modality Therapy | Abdominal Neoplasms - surgery | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fatal Outcome | Adult | Abdominal Neoplasms - pathology | Chemotherapy, Adjuvant | Liver Neoplasms - secondary | Doxorubicin - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: A multicenter non-randomized phase II study
by Santini, Daniele and Massacesi, Cristian and D'Angelillo, Rolando Maria and Marcucci, Fabiana and Campisi, Costantino and Vincenzi, Bruno and Pilone, Alberta and Bianco, Vincenzo and Bonsignori, Maurizio and Tonini, Giuseppe
Medical oncology (Northwood, London, England), ISSN 1357-0560, 2004, Volume 21, Issue 1, pp. 59 - 66
Raltitrexed | First-line chemotherapy | Oxaliplatin | Advanced colorectal cancer | Phase II trial | Life Sciences & Biomedicine | Oncology | Science & Technology | Colorectal Neoplasms - mortality | Follow-Up Studies | Thiophenes - adverse effects | Humans | Middle Aged | Male | Survival Rate | Treatment Outcome | Thiophenes - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - drug therapy | Antimetabolites, Antineoplastic - adverse effects | Quinazolines - adverse effects | Adult | Female | Quinazolines - administration & dosage | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.